Registry of Asthma Characterization and Recruitment 3 (RACR3) (NCT05272241)
Registry of Asthma Characterization and Recruitment 3 (RACR3) (CAUSE-02)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Colorado: Allergy Program — Aurora, Colorado
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Children's Hospital Colorado: Allergy Program — Aurora, Colorado
- Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site — Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology — Chicago, Illinois
- Boston Children's Hospital: Department of Immunology — Boston, Massachusetts
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute — New York, New York
- Columbia University Medical Center: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine — New York, New York
- Cincinnati Children's Hospital Medical Center: Asthma Center — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (720) 777-8077
Email: pascuala.pinedo-estrada@childrenscolorado.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.